User profiles for P.P. Hekking

Pieter-Paul Hekking

Verified email at hekking.com
Cited by 2202

U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics

…, J Haughney, G Hedlin, PP Hekking… - Journal of Allergy and …, 2017 - Elsevier
Background Asthma is a heterogeneous disease in which there is a differential response to
asthma treatments. This heterogeneity needs to be evaluated so that a personalized …

Pathway discovery using transcriptomic profiles in adult-onset severe asthma

PP Hekking, MJ Loza, S Pavlidis, B De Meulder… - Journal of Allergy and …, 2018 - Elsevier
Background Adult-onset severe asthma is characterized by highly symptomatic disease
despite high-intensity asthma treatments. Understanding of the underlying pathways of this …

Identification and prospective stability of electronic nose (eNose)–derived inflammatory phenotypes in patients with severe asthma

P Brinkman, AH Wagener, PP Hekking… - Journal of Allergy and …, 2019 - Elsevier
Background Severe asthma is a heterogeneous condition, as shown by independent cluster
analyses based on demographic, clinical, and inflammatory characteristics. A next step is to …

Comorbidities in difficult-to-control asthma

PP Hekking, M Amelink, RR Wener, ML Bouvy… - The Journal of Allergy …, 2018 - Elsevier
Background Difficult-to-control asthma is associated with significant medical and financial
burden. Comorbidities are known to contribute to uncontrolled asthma. Better insight into the …

Transcriptomic gene signatures associated with persistent airflow limitation in patients with severe asthma

PP Hekking, MJ Loza, S Pavlidis… - European …, 2017 - Eur Respiratory Soc
A proportion of severe asthma patients suffers from persistent airflow limitation (PAL), often
associated with more symptoms and exacerbations. Little is known about the underlying …

[HTML][HTML] Treatable traits in the European U‐BIOPRED adult asthma cohorts

AJ Simpson, PP Hekking, DE Shaw, LJ Fleming… - Allergy, 2019 - ncbi.nlm.nih.gov
Hekking has nothing to disclose; Dr Shaw reports advisory board fees from GSK, Novartis
and AZ and travel fees from TEVA and AZ; Dr. Fleming reports personal fees from Vectura, …

[HTML][HTML] Overuse of oral corticosteroids, underuse of inhaled corticosteroids, and implications for biologic therapy in asthma

K Eger, M Amelink, S Hashimoto, PP Hekking, C Longo… - Respiration, 2022 - karger.com
… This database was also used in a previous study on the prevalence of severe asthma by
Hekking et al. [10]. First, patients with at least 1 ICS prescription between January 1, 2011, and …

[HTML][HTML] Severe COPD: Multidisciplinary Consultation to Get the Right Care at the Right Place

PP Hekking, M van Meggelen, WJ Lie… - … Journal of Chronic …, 2024 - Taylor & Francis
In the Netherlands, approximately 600,000 patients are affected by Chronic Obstructive
Pulmonary Disease (COPD). COPD is a heterogeneous and common disease, and the third …

Anti-IL-5/5Ra biologics improve work productivity and activity in severe asthma: a RAPSODI registry-based cohort study

JPM van der Valk, PP Hekking, SP Rauh… - Journal of …, 2023 - Taylor & Francis
Introduction Severe asthma is associated with a serious disease burden, partially caused by
limitations in activity and work impairment. Aims and objectives This study aims to relate …

Late Breaking Abstract-Overuse of oral corticosteroids in asthma–modifiable factors and potential role of biologics

KAB Eger, M Amelink, PP Hekking, E Bel - 2019 - Eur Respiratory Soc
Background: Asthma patients using high doses of oral corticosteroids are exposed to serious
adverse effects. It is therefore important to know the prevalence and characteristics of these …